Mark McBride, PhD.
Central Nervous System (schizophrenia, Parkinson’s disease, depression, Alzheimer’s, and other psychiatric and neurological disorders), respiratory diseases, pain management, metabolic diseases and oncology
Dr. Mark McBride is co-founder of Instat and has more than 30 years of experience in leadership and management of biostatistics and data management services in the pharmaceutical and biotechnology industry. He specializes in combining strong technical knowledge with customer-focused results.
Dr. McBride’s experience includes statistical analysis and reporting for Phase I-IV studies in various therapeutic areas, including metabolic diseases, oncology, HIV/infectious diseases, pain management, dermatology, and respiratory, with extensive expertise in statistical analyses of Phase I-III studies in the CNS therapeutic area. His CNS experience includes the analysis and management of studies for indications such as Schizophrenia, Parkinson’s Disease, Depression, Alzheimer’s, and other psychiatric and neurological disorders. In addition, he has had responsibility for a variety of statistical activities for key clinical development programs, with experience supporting regulatory components for drug approval. He has represented several pharmaceutical companies in meetings with the FDA and has served as a member of several Data Monitoring Committees (DMCs).
Prior to co-founding Instat, Dr. McBride enjoyed a successful career with a leading CRO where he held a variety of senior management positions, including Senior Vice President, Global Biostatistics and Data Management, with responsibility for managing the global data services business unit. He also led the integration of data groups after the acquisition of various companies to create the Global Biostatistics and Data Management group with common SOPs and systems. He received his Ph.D. in Biostatistics from the University of North Carolina and a BS and MS in Statistics from Brigham Young University.